# Glioblastoma Multiforme Drugs Market and Forecast 2025-2033

Limited-Time Offer \[Flat 15% Discount\] [Dismiss](#)

[Skip to content](#content "Skip to content")

[Updated Data Matrix Available](https://www.ihealthcareanalyst.com/research-services/)

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

[Home](https://www.ihealthcareanalyst.com/) » [Reports](https://www.ihealthcareanalyst.com/shop/) » [Pharmaceuticals](https://www.ihealthcareanalyst.com/reports/pharmaceuticals/)

![Awaiting product image](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)

![Awaiting product image](https://www.ihealthcareanalyst.com/wp-content/uploads/2019/08/report-icon4-e1565791186498.png)

# Glioblastoma Multiforme Drugs Market by Product \[Gliadel Wafer (Polifeprosan 20 with Carmustine Implant), Temodar (temozolomide / TMZ), Avastin (bevacizumab), Tafinlar (dabrafenib) + Mekinist (trametinib), Voranigo (vorasidenib), Ojemda (tovorafenib)\], Pipeline Analysis, and Forecast 2025-2033

$3,000.00

## Report Specifications: Market Size, Market Share, Growth Trends, Forecast, Geography

_Glioblastoma multiforme_ (GBM), also known as glioblastoma and grade IV astrocytoma, is the most common and most aggressive cancer that begins within the brain. Uncommon risk factors include genetic disorders such as neurofibromatosis and Li Fraumeni syndrome and previous radiation therapy.

Typically, treatment involves surgery after which chemotherapy and radiation therapy is used. The medication temozolomide is frequently used as part of chemotherapy, whereas high dose steroids are used to help reduce swelling and decrease symptoms.

The global G_lioblastoma multiforme_ drugs market report provides market size ($Million 2023 to 2033), market share, market trends and forecast (CAGR%, 2025 to 2033).

The global _Glioblastoma multiforme_ drugs market segmented by product \[Gliadel Wafer (polifeprosan 20 with carmustine implant), Temodar (temozolomide / TMZ), Avastin (bevacizumab), Tafinlar (dabrafenib) + Mekinist (trametinib), Voranigo (vorasidenib), Ojemda (tovorafenib)\], pipeline analysis, and geography.

The global G_lioblastoma multiforme_ drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

The Temozolomide segment accounted for the largest share of the global G_lioblastoma multiforme_ drugs market, while Bevacizumab (Avastin) was the fastest growing segment during the forecast period. Rising geriatric population, increasing awareness campaigns and introduction of new technologies are driving the global g_lioblastoma multiforme_ drugs market. North America accounted for the largest market share, followed by Asia Pacific region.

The global G_lioblastoma multiforme_ treatment market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major players operating in the global glioblastoma multiforme treatment market market and included in this report are Azurity Pharmaceuticals, Inc., Day One Biopharmaceuticals, LLC. Les Laboratoires Servier, Merck & Co., Inc., Novartis AG, Roche Holding AG (Genentech, Inc.).

**DATA INCLUDED:** Glioblastoma multiforme Drugs Market Size, Glioblastoma multiforme Drugs Market Share, Glioblastoma multiforme Drugs Market Growth Rates, Glioblastoma multiforme Drugs Market Trends, and Glioblastoma multiforme Drugs Market Forecast to 2033

**Market Data:**

*   Estimation Base Year: 2024
*   Historical Data Range: 2023-2024
*   Forecast Period: 2025-2033
*   Market Representation: Revenue in $million and CAGR % from 2025 to 2033
*   Regional Scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
*   Country Scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE, and other countries.
*   Report Coverage: Revenue forecasts, company market share, competitive landscape analysis, growth factors, and market trends
*   Customization Scope (15% Free): Accommodation of specific or custom requirements beyond the current report scope.

**Qualitative Analysis:**

*   Industry Overview
*   Industry Trends
*   Market Driver, Restraints, and Opportunities
*   Market Size
*   Growth Trends
*   Porter’s Five Forces Analysis
*   Market Attractiveness Matrix
*   Competitive Landscape
    *   Company Overview
    *   Financial Performance
    *   Product Portfolio
    *   Strategic Insights
    *   Recent Developments

**Quantitative Analysis:**

*   Market Size Projections: Comprehensive estimates and forecasts for all segments
*   Regional Market Analysis: Estimates and forecasts for key countries
*   Corporate Financial Performance: Analysis of company financials
*   Competitive Landscape: Market share analysis of leading companies

Choose License Type

Choose an optionSingle-user LicenseMulti-user LicenseCorporate License[Clear](#)

Glioblastoma Multiforme Drugs Market by Product \[Gliadel Wafer (Polifeprosan 20 with Carmustine Implant), Temodar (temozolomide / TMZ), Avastin (bevacizumab), Tafinlar (dabrafenib) + Mekinist (trametinib), Voranigo (vorasidenib), Ojemda (tovorafenib)\], Pipeline Analysis, and Forecast 2025-2033 quantity 

Buy Report   

For inquiries regarding discounts on single or bundled report purchases, please reach out to us.

*   [Table of Contents PH](#tab-table-of-contents-ph)
*   [Market Segments and Companies](#tab-market-segments-and-companies)
*   [Request ToC / Sample](#tab-request-toc-sample)

1.  **Introduction**
2.  **Executive Summary**
    *   Market Size Estimation ($million, 2023-2033)
    *   Forecast Estimation ($million and CAGR%, 2025-2033)
3.  [**Research Methodology**](https://www.ihealthcareanalyst.com/research-methodology/)
4.  **Market Landscape**
    *   Market Dynamics
        *   Drivers
        *   Barriers
        *   Opportunities
    *   Market Share Analysis
        *   Companies
        *   Drugs
    *   Market Trends Analysis
        *   Key success factors
        *   Market Growth Rate
    *   Market Attractiveness Analysis
    *   Market Profitability Analysis
        *   Buyer power
        *   Supplier power
        *   Barriers to entry
        *   Threat of substitute products
        *   Rivalry among firms in the industry
    *   Distribution Channels
5.  **Market Segmentation** \[_refer Market Segments and Companies Tab_\]
    *   Drug Class or Drug (Brand) Type
    *   Drug or Disorder Test
    *   Indication Type
    *   Drug Treatment
    *   Mechanism of Action
    *   Therapeutic Area or Nature of Application
    *   End User Groups
6.  **Geography (Region, Country)**
    *   North America (U.S., Canada)
    *   Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    *   Asia Pacific (Japan, China, India, Rest of APAC)
    *   Latin America (Brazil, Mexico, Rest of LA)
    *   Rest of the World (Middle East & Africa)
7.  **Regulatory Overview** 
    *   IND, NDA filed, FDA, EMEA Approvals
8.  **Pipeline Analysis** (Phase 1, 2 and 3 Drugs)
    *   Phase 3 Drugs Forecast Estimation (Approval to 2033)
    *   Phase 1 and 2 Drugs – Qualitative Analysis
9.  **Company Profiles** \[_refer Market Segments and Companies Tab_\]
    *   Company Overview
    *   Financial Snapshot
    *   Product Portfolio
    *   Business Strategies
    *   Recent Developments
10.  **Recommendations**
11.  **References**

**Key Questions Answered:**  
1\. What are the factors driving and limiting this market, key success factors and challenges?  
2\. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?  
3\. How do markets perform between countries and regions?  
4\. What market segments are contributing to maximum share and greatest growth?  
5\. What is the product or procedure volumes by country and regions?

**Actionable Insights Included:**  
1\. Product portfolio matrix (Share vs. Growth)  
2\. Market attractiveness (Region vs. Growth)  
3\. Spot matrix (Product vs. Region)  
4\. Geographic distribution matrix (Share vs. Growth)

**_Glioblastoma multiforme_ Drugs Market**

1\. **Product**  
1.1. Gliadel Wafer (Polifeprosan 20 with carmustine implant) (BCNU, bischloroethylnitrosourea)  
1.2. Temodar (temozolomide) TMZ  
1.3. Avastin (bevacizumab)  
1.4. Tafinlar (dabrafenib) + Mekinist (trametinib)  
1.5. Voranigo (vorasidenib)  
1.6. Ojemda (tovorafenib)

2\. **Pipeline Analysis**  
2.1. DCVax-L  
2.2. Eflomithine  
2.3. Lextemy  
2.4. Marizomib  
2.5. ONC201  
2.6. OT-101  
2.7. VAL-083  
2.8. DB107  
2.9. ADI-PEG 20  
2.10. Paxalisib  
2.11. Troriluzole  
2.12. VT1021

3\. **Geography**  
3.1. North America (U.S., Canada)  
3.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)  
3.3. Asia Pacific (Japan, China, India, Rest of APAC)  
3.4. Latin America (Brazil, Mexico, Rest of LA)  
3.5. Rest of the World

4\. **Company Profiles**  
4.1. Azurity Pharmaceuticals, Inc.  
4.2. Day One Biopharmaceuticals, LLC  
4.3. Les Laboratoires Servier  
4.4. Merck & Co., Inc.  
4.5. Novartis AG  
4.6. Roche Holding AG (Genentech, Inc.)

**Request Table of Contents / Sample Report**

Full Name\*

Company Email\*

Phone Number\* \[Please add country code\]

Subject\*

Message\*

Resource Links

*   [About Us](https://www.ihealthcareanalyst.com/about/)
*   [Clinical Trials](https://www.ihealthcareanalyst.com/clinical-trials-dashboard/)
*   [Drugs@FDA](https://www.ihealthcareanalyst.com/drugs-fda-dashboard/)
*   [Orange Book](https://www.ihealthcareanalyst.com/orange-book-dashboard/)
*   [Premarket Approval](https://www.ihealthcareanalyst.com/premarket-approval-pma/)
*   [Premarket Notification](https://www.ihealthcareanalyst.com/premarket-notification-510k/)
*   [Publications](https://www.ihealthcareanalyst.com/publications/)

Terms and Conditions

*   [FAQs](https://www.ihealthcareanalyst.com/faqs/)
*   [Careers](https://www.ihealthcareanalyst.com/careers/)
*   [Terms of Use](https://www.ihealthcareanalyst.com/terms/)
*   [How to Order](https://www.ihealthcareanalyst.com/order/)
*   [Return Policy](https://www.ihealthcareanalyst.com/return/)
*   [Privacy Policy](https://www.ihealthcareanalyst.com/privacy/)
*   [Disclaimer Policy](https://www.ihealthcareanalyst.com/disclaimer/)

Secure Online Payment

![iHealthcareAnalyst, Inc.](https://www.ihealthcareanalyst.com/wp-content/uploads/2018/07/creditcard-payment-logos-300x48.jpg)

Search

Search

Contact Address

**US Office:** 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States  
Phone: +1 (314) 315-4764  
**India Office:** 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India  
Phone: +91 (20) 25898524  
Email: [\[email protected\]](/cdn-cgi/l/email-protection#d2a1b3beb7a192bbbab7b3bea6bab1b3a0b7b3bcb3beaba1a6fcb1bdbf)

[](# "Scroll back to top")

Search for: